Skip to main content
. Author manuscript; available in PMC: 2008 May 5.
Published in final edited form as: J Clin Oncol. 2004 Oct 13;22(22):4463–4473. doi: 10.1200/JCO.2004.11.035

Fig 2.

Fig 2

Mean (+ SE) percentage of peripheral-blood mononuclear cell–expressing marker before treatment (day 1) and on day 8 for (A) patients completing course 1 and (B) patients completing courses 1 and 2 at the same dose level. Significant differences are shown for (A) day 1 versus day 8 and (B) for course 2 versus course 1. (*), P < .05; (**), P < .01.